Tuesday, July 15, 2025 8:19:52 PM
Better Check before you say NO NO and NO to George on this one....
Sigma 1 Receptor: a novel therapeutic target in retinal ...
National Institutes of Health (NIH) | (.gov)
https://pmc.ncbi.nlm.nih.gov › articles › PMC6557374
by SB Smith · 2018 · Cited by 65 — The collective evidence from analysis of studies over the past 20 years is that Sig1R plays a key role in modulating retinal cellular stress and that it holds ...
Activation of Sigma 1 Receptor Preserves Visual Function ...
National Institutes of Health (NIH) | (.gov)
https://pmc.ncbi.nlm.nih.gov › articles › PMC12240203
by J Wang · 2025 — Previous research has indicated that sigma 1 receptor (Sig1R) activation can help retinal ganglion cells (RGCs) survive optic nerve injur
That is just a quick google check... I guess now your going to say that NIH.GOV is full of bull? Prior to George's comment I hadn't a clue either. But tough to argue with statements from NIH.
I also have been here 10 years. I SOLD ALL in Feb 2021... bought another rental house with some of the money. Later when the price crashed I started buying back in. I now have almost as many shares as I had back in 2021 when I sold ALL. Yes I am about 70% Real Estate ... I also don't hide behind some moniker. Easy to find me. Federal Amateur Radio license. We can't hide.
John k9uwa
Sigma 1 Receptor: a novel therapeutic target in retinal ...
National Institutes of Health (NIH) | (.gov)
https://pmc.ncbi.nlm.nih.gov › articles › PMC6557374
by SB Smith · 2018 · Cited by 65 — The collective evidence from analysis of studies over the past 20 years is that Sig1R plays a key role in modulating retinal cellular stress and that it holds ...
Activation of Sigma 1 Receptor Preserves Visual Function ...
National Institutes of Health (NIH) | (.gov)
https://pmc.ncbi.nlm.nih.gov › articles › PMC12240203
by J Wang · 2025 — Previous research has indicated that sigma 1 receptor (Sig1R) activation can help retinal ganglion cells (RGCs) survive optic nerve injur
That is just a quick google check... I guess now your going to say that NIH.GOV is full of bull? Prior to George's comment I hadn't a clue either. But tough to argue with statements from NIH.
I also have been here 10 years. I SOLD ALL in Feb 2021... bought another rental house with some of the money. Later when the price crashed I started buying back in. I now have almost as many shares as I had back in 2021 when I sold ALL. Yes I am about 70% Real Estate ... I also don't hide behind some moniker. Easy to find me. Federal Amateur Radio license. We can't hide.
John k9uwa
Bullish
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
